Previous studies have demonstrated that PTL’s anti-cancer activity within liver cancer cells is due to halted cell cycle progression at the G2/M phase by p53 activation and arrested cells in the G0-G1 through a decrease in cyclin D1 expression (Wen et al., 2002; Ralstin et al., 2006). Here, TP53 is linked to liver cancer.